News
BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs
Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs
January 29, 2025
BioLoomics Appoints Kurt Gish as Chief Scientific Officer to Advance Development of Improved ADCs
Former CSO of Trilo Therapeutics and Research Fellow atAbbVie joins to lead BioLoomics’ pipeline and combine lysosome targetingantibodies with ADCs
Press
Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders
BioLoomics’ goal is to make a degrader from an antibody in one month
Press
BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies
Our mission is to make safer, more effective cancer therapeutics.
News
